2006 AAHA Canine Vaccine Guideliness

Journal of the American Animal Hospital Association

Volumn 42, Issue 2, 2006, Pages 80-89

  Paul, Michael A ^a   Carmichael, Leland E ^a   Childers, Henry ^a   Cotter, Susan ^a   Davidson, Autumn ^a   Ford, Richard ^a   Hurley, Kate F ^a   Roth, James A ^a   Schultz, Ronald D ^a   Thacker, Eileen ^a   Welborn, Link ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; CORONA VIRUS VACCINE; MEASLES VACCINE; PARAINFLUENZA VACCINE; PARVOVIRUS VACCINE; PERTUSSIS VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADENOVIRUS; ARTICLE; BORDETELLA BRONCHISEPTICA; CANINE DISTEMPER MORBILLIVIRUS; CORONAVIRUS; DOG DISEASE; DRUG DOSE REGIMEN; DRUG INFORMATION; DRUG USE; GIARDIA LAMBLIA; HEALTH CARE AVAILABILITY; INDIVIDUALIZATION; INTERNET; LEPTOSPIRA INTERROGANS; LICENSING; LIFESTYLE; MEASLES VIRUS; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; NONHUMAN; PARVOVIRUS; PORPHYROMONAS; PRACTICE GUIDELINE; PUBLICATION; RABIES; RISK FACTOR; SNAKE; VACCINATION; VIRUS INFECTION;

ADENOVIRIDAE; BORDETELLA BRONCHISEPTICA; CANINE DISTEMPER VIRUS; CANIS FAMILIARIS; CORONAVIRUS; GIARDIA INTESTINALIS; LEPTOSPIRA INTERROGANS; MEASLES VIRUS; PARVOVIRUS; PORPHYROMONAS;

EID: 33644979116     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0420080     Document Type: Article

References (55)

1. American Animal Hospital Association Canine Vaccine Task Force. Report of the AAHA canine vaccine task force: executive summary and 2003 canine vaccine guidelines, recommendations. J Am Anim Hosp Assoc 2003;39:119-131.
2. Mouzin DE, Lorenzen MJ, Haworth JD et al. Duration of immunity in dogs after vaccination or naturally acquired infection. J Am Vet Med Assoc 2004;224:55-60.
3. Schultz RD et al. Information provided at International Vaccines and Diagnostics Conf, Guelph, Ontario, Canada, 2003.
4. Carmichael LE. Canine viral vaccines at a turning point - A personal perspective. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. San Diego: Academic Press, 1999:289-307.
5. Bowman D. Companion Animal Parasite Council Guidelines. North Am Vet Conf, Orlando, FL, 2004.
6. Roth JA, Henderson LM. New technology for improved vaccine safety and efficacy. Vet Clin North Am Food Anim Pract 2001;17:585-597.
7. Spickler AR, Roth JA. Adjuvants in veterinary vaccines: modes of action and side effects. J Vet Intern Med 2003;17:273-281.
8. Pardo MC, Bauman JE, Mackowiak M. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glyco-proteins. Am J Vet Res 1997;58:833-836.
9. Levy SA, Clark KK, Glickman LT. Infection rates in dogs vaccinated and not vaccinated with an OspA Borrelia burgdorferi vaccine in a Lyme disease-endemic area of Connecticut. Intl J of Appl Res 2005; 3:1-5.
10. Pastoret PP. Veterinary vaccinology. CR Acad Sci 1999;322:967-972.
11. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and induction of immunity. J Leuk Biol 2000;68:793-806.
12. USDA issues license for West Nile virus DNA vaccine for horses. Press release of July 18, 2005. http://www.aphis.usda.gov/pa/news/2005/07/wnvdna-vs.html.
13. Animals and animal products. Viruses, serums, toxins, and analogous products. Testing terminology; pure or purity (9 CFR 101.5 (c)). Fed Reg Apr 18, 1997;62:19037.
14. Animals and animal products. Viruses, serums, toxins, and analogous products. Testing terminology; safe or safety (9 CFR 101.5 (d)). Fed Reg Apr 18, 1997;62:19037.
15. Animals and animal products. Viruses, serums, toxins, and analogous products. Testing terminology; potent or portency (9 CFR 101.5 (f)). Fed Reg Apr 18, 1997;62:19037.
16. Animals and animal products (9 CFR 101). Fed Reg Apr 18, 1997, 62:19037.
17. Animals and animal products. Viruses, serums, toxins, and analogous products. Testing terminology; efficacious or efficacy (9 CFR 101.5 (g)). Fed Reg Apr 18, 1997;62:19037.
18. Aubert M. Practical significance of rabies antibodies in cats and dogs. Rev Sci Tech Off Int Epiz 1992;11:735-760.
19. Böhm M, Thompson H, Weir A et al. Serum antibody titres to canine parvovirus, adenovirus, and distemper. Vet Rec 2004;154:457-462.
20. Greene CE, ed. Immunoprophylaxis and immunotherapy. In: Infectious Diseases of the Dog and Cat. 2nd ed. Philadelphia: WB Saunders, 1998:723-744.
21. Larson LJ, Schultz RD. High-titer canine parvovirus vaccine: serologic response and challenge-of-immunity study. Vet Med 1996; 91:210-218.
22. Mansfield PD. Vaccination of dogs and cats in veterinary teaching hospitals in North America. J Am Vet Med Assoc 1996;208:1242-1247.
23. Neimeier-Forster M. Duration of immunity study in dogs as determined by serologic testing of canine distemper, parvovirosis and rabies. Thesis, Vetsuisse Univ, Berne, Switzerland 2004.
24. Olson P, Klingeborn B, Hedhammar A. Serum antibody response to canine parvovirus, canine adenovirus-1, and canine distemper virus in dogs with known status of immunization: study of dogs in Sweden. Am J Vet Res 1988;49:1460-1466.
25. Pyrdie J. Persistence of antibodies following vaccination against canine distemper and the effect of revaccination. Vet Rec 1966;78:486-488.
26. Rikula U, Nuotio L, Sihvonen L. Canine distemper virus neutralizing antibodies in vaccinated dogs. Vet Rec 2000;147:598-603.
27. Schultz RD. Current and future canine and feline vaccination programs. Vet Med 1998;93:3:233-254.
28. Tizard I, Ni YW. Use of serologic testing to assess immune status of companion animals. J Am Vet Med Assoc 1998;213:54-60.
29. Twark L, Dodds WJ. Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs. J Am Vet Med Assoc 2000;217:1021-1024.
30. Appel M, Robson DS. A microneutralization test for canine distemper virus. Am J Vet Res 1973;34:1459-1463.
31. Chappuis G. Control of canine distemper. Vet Microbiol 1995; 44:351-358.
32. Carmichael LE, Joubert JC, Pollock RV. A modified live canine parvovirus vaccine. II. Immune response. Cornell Vet 1983;73:13-29.
33. Schultz RD, Ford RB, Olsen J et al. Titer testing and vaccination: a new look at traditional practices. Vet Med 2002;97(2):1-13.
34. Appel MJG. Forty years of canine vaccination. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. San Diego: Academic Press, 1999;309-324.
35. Schultz RD, Conklin S. The immune system and vaccines. Compend Contin Educ Pract Vet 1998;20:5-18.
36. Roth JA. Mechanistic bases for adverse vaccine reactions and vaccine failures. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. San Diego: Academic Press, 1999;681-700.
37. Schultz RD, Appel MJ, Carmichael LE et al. Canine vaccines and immunity. In: Kirk RW, ed. Current Veterinary Therapy VI. Philadelphia: WB Saunders, 1977;1271-1275.
38. Olson P, Finnsdottir H, Klingeborn B et al. Duration of antibodies elicited by canine distemper virus vaccinations in dogs. Vet Rec 1997; 141:654-655.
39. Abdelmagid OY, Larson L, Payne L et al. Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges. Vet Therapeutics 2004;5:173-186.
40. Schultz RD. Information presented at Central Veterinary Conf, Kansas City, MO, 2005.
41. Cliquet F, Aubert M, Sagne L. Development of a fluorescent antibody virus neutralization test (FAVN test) for the quantitation of rabies-neutralizing antibody. J Immun Methods 1998;212:79-87.
42. Cliquet F et al. Neutralizing antibody titration in 25,000 sera of dogs and cats vaccinated against rabies in France, in the framework of the new regulations that offer an alternative to quarantine. Rev Sci Tech 2003;22:857-866.
43. 67 Fed Reg 1910 (2002) proposed Jan 15, 2002; withdrawn at 70 Fed Reg 4325 (2005).
44. 70 Fed Reg 48325b (2005) proposed Aug 15, 2005.
45. Principles of vaccination. J Am Vet Med Assoc 2001;219:575-576.
46. Greene CE, Schultz RD. Immunoprophylaxis and immunotherapy. In: Infectious Diseases of the Dog and Cat. 3rd ed. Philadelphia: WB Saunders, 2005:1069-1119.
47. Schultz R. Canine distemper and vaccination. Duluth, GA: Merial, 2005.
48. Edinboro CH, Ward MP, Glickman LT. A placebo-controlled trial of two intranasal vaccines to prevent tracheobronchitis (kennel cough) in dogs entering a humane shelter. Prev Vet Med 2004;62:89-99.
49. Glickman LT, Appel MJ. Intranasal vaccine trial for canine infectious tracheobronchitis (kennel cough). Lab Anim Sci 1981;31:397-399.
50. Bey RF, Shade FJ, Goodnow RA et al. Intranasal vaccination of dogs with live avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. Am J Vet Res 1981;42:1130-1132.
51. Ellis JA, Krakowska GS, Dayton AD et al. Comparative efficacy of an injectable vaccine and an intranasal vaccine in stimulating Bordetella bronchiseptica-reactive antibody responses in seroptive dogs. J Am Vet Med Assoc 2002;220:43-48.
52. Schroeder JP, Bordt DW, Mitchell FE. Studies of canine distemper immunization of puppies in a caninie distemper-contaminated environment. Vet Med Small Anim Clin 1967;62:782-787.
53. Centers for Diseases Control and Prevention. General recommendations on immunization:recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2002;51(RR-2):18-19.
54. Greene CE, ed. Immunoprophylaxis and immunotherapy In: Infectious Disease of the Dog and Cat. 2nd ed. Philadelphia: WB Saunders, 1998:717-750.
55. Miyamoto T, Taura Y, Une S et al. Immunological responces after vaccination pre- and post-surgery in dogs. J Vet Med Sci 1995: 57(1):29-32.